{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"fd30cbb00e0cd4ef6c79a3cc14861c9f3b37aa1b5fc0036043748e05d67e1a09","attributes":{"feedName":"medwatch","feedSource":"medwatch","title":"Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose","description":"Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose","link":"http://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death","publicationDate":"2019-07-26T14:06:52.000Z","state":"sent","affected":[],"allergens":[],"audience":["professionals"],"categories":["drugs"],"contaminants":[],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5d9e68eb8b079e002a25218b"}}}